Sonoma Pharmaceuticals
SNOA
18 hedge funds and large institutions have $726K invested in Sonoma Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.01% less ownership
Funds ownership: 0.29% → 0.28% (-0.01%)
16% less capital invested
Capital invested by funds: $860K → $726K (-$134K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$138K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.32K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$98.1K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$68K |
| 3 |
Morgan Stanley
New York
|
-$8.82K |
| 4 |
Renaissance Technologies
New York
|
-$6.87K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $242K | -$6.87K | -95 | -3% |
|
|
TSS
2
Two Sigma Securities
New York
| $153K | +$138K | +1,906 | New |
|
3
Geode Capital Management
Boston,
Massachusetts
| $147K | – | – | – |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $111K | -$98.1K | -1,357 | -50% |
|
|
HFS
5
HBC Financial Services
Seattle,
Washington
| $39K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $15K | +$8.32K | +115 | +160% |
|
7
BlackRock
New York
| $11K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $5K | +$3.04K | +42 | +162% |
|
9
US Bancorp
Minneapolis,
Minnesota
| $2K | – | – | – |
|
10
Osaic Holdings
Scottsdale,
Arizona
| $1K | – | – | – |
|
|
11
Dimensional Fund Advisors
Austin,
Texas
| – | -$68K | -750 | Closed |
|
|
12
Morgan Stanley
New York
| – | -$8.82K | -122 | -96% |
|
SNOA Hedge Fund Activity: Q1 2022 in Review
18 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2022, worth a combined $726K — down 16% from $860K a quarter earlier.
Fund positioning in SNOA was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $138K. The largest seller was Vanguard Group, cutting an estimated $98.1K.
- 18 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $726K of Sonoma Pharmaceuticals stock for Q1 2022, down 16% quarter-over-quarter.
- 1 fund opened new Sonoma Pharmaceuticals positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest Sonoma Pharmaceuticals buyer in Q1 2022 was Two Sigma Securities, an estimated $138K added.
- The largest Sonoma Pharmaceuticals seller in Q1 2022 was Vanguard Group, an estimated $98.1K sold.
Based on aggregated 13F filings for Q1 2022.